Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 8/20 | 0.55 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | GLP1R | P43220 | 8/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25366110 | 1.00 | PTGER4 (0.55) | PTGER4CNR2GLP1RL3MBTL1KDM4C | |
| SCHEMBL27154428 | 0.91 | GLP1R (0.50) | GLP1R | |
| SCHEMBL20266411 | 0.91 | GLP1R (0.50) | GLP1R | |
| SCHEMBL20266409 | 0.91 | GLP1R (0.50) | GLP1R | |
| SCHEMBL26039133 | 0.87 | KDM4E (0.51) | PTGER4CNR2 | |
| SCHEMBL24306324 | 0.87 | KDM4E (0.51) | PTGER4CNR2 | |
| SCHEMBL26046966 | 0.87 | KDM4E (0.51) | PTGER4CNR2 | |
| SCHEMBL31140527 | 0.85 | PTGER4 (0.58) | PTGER4CNR2L3MBTL1KDM4C | |
| SCHEMBL26914167 | 0.84 | CNR2 (0.43) | PTGER4CNR2 | |
| SCHEMBL26914171 | 0.84 | CNR2 (0.43) | PTGER4CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083886-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-03-14 | — | — | US | disclosed |
| US-20230391760-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-12-07 | — | — | US | disclosed |
| WO-2023164358-A1 | GLP-1R MODULATING COMPOUNDS | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-08-31 | — | — | WO | disclosed |
| US-20230271949-A1 | GLP-1R MODULATING COMPOUNDS | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391760-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | PTGER4 431/4885CNR2 747/4885GLP1R 1/4885 |
| US-20230271949-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | PTGER4 1597/4885CNR2 997/4885GLP1R 1/4885 |
| US-20240083886-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | PTGER4 438/4885CNR2 812/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.